Computational Modelling of Schizophrenic Symptoms: Basic Issues

Abstract

Emerging “(computational) systems medicine” challenges neuropsychiatry regarding the development of heuristic computational brain models which help to explore symptoms and syndromes of mental disorders. This methodology of exploratory modelling of mental functions and processes and of their pathology requires a clear and operational definition of the target variable (explanandum). In the case of schizophrenia, a complex and heterogeneous disorder, single psychopathological key symptoms such as working memory deficiency, hallucination or delusion need to be defined first. Thereafter, measures of brain structures can be used in a multilevel view as biological correlates of these symptoms. Then, in order to formally “explain” the symptoms, a qualitative model can be constructed. In another step, numerical values have to be integrated into the model and exploratory computer simulations can be performed. Normal and pathological functioning is to be tested in computer experiments allowing the formulation of new hypotheses and questions for empirical research. However, the crucial challenge is to point out the appropriate degree of complexity (or simplicity) of these models, which is required in order to achieve an epistemic value that might lead to new hypothetical explanatory models and could stimulate new empirical and theoretical research. Some outlines of these methodological issues are discussed here, regarding the fact that measurements alone are not sufficient to build models.

Key words

methodology - qualitative modelling - quantitative modelling - complexity - simulation

• References

• 1 EU From . Systems Biology to Systems Medicine. In: Brussels June 14–15, 2010: Report on European Commission. DG Research, Directorate of Health, Workshop; 2010
• 2 Tretter F. Systemwissenschaft in der Medizin. Deutsches Ärzteblatt 1989; 82: A3198
• 3 Tegner JN, Compte A, Auffray C et al. Computational disease modelling – fact or fiction?. BMC Syst Biol 2009; 3: 56
• 4 Belair J, Glass L. an der Heiden U, et al. eds. Dynamical disease – mathematical analysis of human illness. Woodbury, USA: American Institute of Physics; 1995
• 5 Noble D. Multilevel Modelling in Systems Biology: From Cells to Whole Organs. In: Szallasi Z, Periwal V, Stelling J. eds. System Modelling in Cellular Biology. Cambridge, MA: MIT Press; 2006: 297-312
• 6 Kitano H. Systems biology: a brief overview. Science 2002; 295: 1662-1664
• 7 Klipp E, Herwig R, Kowald A et al. Systems Biology in Practice. Weinheim: Wiley-VCH; 2005
• 8 Breen G, McGuffin P, Simmons A. Towards “systems psychiatry”. Rev Bras Psiquiatr 2008; 30: 97-98
• 9 Tretter F, Gebicke-Haerter PJ, Mendoza ER, et al. eds. Systems biology in psychiatric research: From high-throughput data to mathematical modelling. Weinheim: Wiley-VCH; 2010
• 10 Craver C. Explaining the Brain. New York: Oxford University Press; 2007
• 11 Bickle J. Philosophy and Neuroscience: A Ruthlessly Reductive Account. Studies in Brain and Mind. Amsterdam: Springer; 2003
• 12 Dayan P, Abbott L. Theoretical Neuroscience. Computational and mathematical modelling of neural systems. Cambridge, MA: MIT Press; 2005
• 13 Le Novere N, Hucka M, Mi H et al. The Systems Biology Graphical Notation. Nat Biotechnol 2009; 27: 735-741
• 14 Matthäus F, Smith VA, Gebicke-Haerter PJ. Some useful mathematical tools to transform microarray data into interactive molecular networks. In: Tretter F, Gebicke-Haerter PJ, Mendoza ER, Winterer G. eds. Systems biology in psychiatric research: From high-throughput data to mathematical modelling. Weinheim: Wiley-VCH; 2010
• 15 Tretter F. Philosophical aspects of neuropsychiatry. In: Tretter F, Gebicke-Haerter PJ, Mendoza ER, Winterer G. eds. Systems biology in psychiatric research: From high-throughput data to mathematical modelling. Weinheim: Wiley-VCH; 2010: 3-25
• 16 Andreasen NC. Positive and negative symptoms: historical and conceptual aspects. Mod Probl Pharmacopsychiatry 1990; 24: 1-42
• 17 Goldman-Rakic PS. Cellular basis of working memory. Neuron 1995; 14: 477-485
• 18 Goldman-Rakic PS. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999; 46: 650-661
• 19 Forrester JW. Urban Dynamics. Pegasus Communications; 1969
• 20 Sterman JD. Learning from evidence in a complex world. Am J Public Health 2006; 96: 505-514
• 21 Singer W. Neurobiology. Striving for coherence. Nature 1999; 397 (391) 393
• 22 Freeman W. Neurodynamics. New York: Springer; 2000
• 23 Buzsaki G. Rhythms of the brain. New York: Oxford University Press; 2006
• 24 Herz AV, Gollisch T, Machens CK et al. Modelling single-neuron dynamics and computations: a balance of detail and abstraction. Science 2006; 314: 80-85
• 25 Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-186
• 26 Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl. 01) S10-S14
• 27 an der Heiden U. Schizophrenia as a dynamical disease. Pharmacopsychiatry 2006; 39 (Suppl. 01) S36-S42
• 28 Schwegler H. Phenomenological modelling of some mechanisms in schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl. 01) S43-S49
• 29 Carlsson A, Waters N, Holm-Waters S et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41: 237-260
• 30 Goto Y, Grace AA. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. Int Rev Neurobiol 2007; 78: 41-68
• 31 Meyer-Lindenberg A. Neuroimaging and the question of neurodegeneration in schizophrenia. Prog Neurobiol 2011; 95: 514-516
• 32 Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 2007; 78: 1-39
• 33 Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 2003; 1003: 138-158
• 34 Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004; 7 (Suppl. 01) S1-S5
• 35 Abi-Dargham A, Guillin O. Integrating the neurobiology of schizophrenia. Preface. Int Rev Neurobiol 2007; 78: xiii-xvi
• 36 Berman JA, Talmage DA, Role LW. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol 2007; 78: 193-223
• 37 Leicht G, Karch S, Karamatskos E et al. Alterations of the early auditory evoked gamma-band response in first-degree relatives of patients with schizophrenia: hints to a new intermediate phenotype. J Psychiatr Res 2011; 45: 699-705
• 38 Leicht G, Kirsch V, Giegling I et al. Reduced early auditory evoked gamma-band response in patients with schizophrenia. Biol Psychiatry 2010; 67: 224-231
• 39 Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010; 36: 472-485
• 40 Schlagenhauf F, Sterzer P, Schmack K et al. Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 2009; 65: 1032-1039
• 41 Schlosser RG, Koch K, Wagner G et al. Inefficient executive cognitive control in schizophrenia is preceded by altered functional activation during information encoding: an fMRI study. Neuropsychologia 2008; 46: 336-347
• 42 Schlosser RG, Nenadic I, Wagner G et al. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr Res 2007; 89: 1-11
• 43 Lisman JE, Coyle JT, Green RW et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-242
• 44 Grunze HC, Rainnie DG, Hasselmo ME et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996; 16: 2034-2043
• 45 Rujescu D, Bender A, Keck M et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 2006; 59: 721-729
• 46 Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-324
• 47 Whittington MA, Traub RD. Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci 2003; 26: 676-682
• 48 Fuchs EC, Zivkovic AR, Cunningham MO et al. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron 2007; 53: 591-604
• 49 Tost H, Meyer-Lindenberg A. Dopamine-glutamate interactions: a neural convergence mechanism of common schizophrenia risk variants. Biol Psychiatry 2011; 69: 912-913
• 50 Mayberg HS. Defining neurocircuits in depression. Psychiatric Annals 2006; 36: 4
• 51 Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010; 35: 192-216
• 52 Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40: 881-884
• 53 Tretter F, Albus M. Systems biology and psychiatry – modelling molecular and cellular networks of mental disorders. Pharmacopsychiatry 2008; 41 (Suppl. 01) S2-S18
• 54 Lindskog M. Modelling of DARPP-32 regulation to understand intracellular signaling in psychiatric disease. Pharmacopsychiatry 2008; 41 (Suppl. 01) S99-S104
• 55 Qi Z, Miller GW, Voit EO. A mathematical model of presynaptic dopamine homeostasis: implications for schizophrenia. Pharmacopsychiatry 2008; 41 (Suppl. 01) S89-S98
• 56 Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160